Mustang Bio, a Fortress Biotech company, is focused on the development of novel immunotherapies and gene therapies in areas of unmet need.
Worcester, MA
Joined October 2017
- Tweets354
- Following178
- Followers2.3K
- Likes53
Rare Disease Day highlights a global challenge: 300+ million people are affected by rare diseases, many with limited or no treatment options.
At Mustang Bio, we’re advancing innovative therapies for devastating conditions, including glioblastoma, an aggressive and rare brain cancer with significant unmet need.
On Rare Disease Day, we are proud to be a part of the global rare disease community and remain driven by one goal: progress for patients. #RareDiseaseDay #Glioblastoma #MustangBio
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma $MBIO $FBIO bit.ly/40BOOzp
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy $MBIO $FBIO bit.ly/4b5bLNd
Mustang Bio announces expansion into #autoimmunediseases with MB-106, a CD20-targeted autologous CAR T-cell therapy. A Phase 1 trial is expected to initiate in the 4th quarter of this year to demonstrate clinical proof-of-concept. $MBIO Learn more: bit.ly/4azqUGS
Mustang Bio reports full-year 2023 financial results and recent corporate highlights. $MBIO Read more here: bit.ly/3Vdj7Kk
Phase 1 data published in @NatureMedicine demonstrate the promising safety and clinical activity of Mustang’s MB-101 IL13Ra2-targeted CAR T-cells for the treatment of patients with recurrent and refractory malignant glioma, including #glioblastoma. $MBIO
#DYK one out every 10 Americans is living with a rare disease? This #RareDiseaseDay, learn more about Mustang's pipeline and its treatments for rare diseases. bit.ly/3Ij0flf #XSCID #BubbleBoyDisease #WaldenstromMacroglobulinemia #GBM $MBIO
#DYK Waldenstrom Macroglobulinemia (WM) is a rare #bloodcancer that originates from malignant B-cells and there is no FDA-approved therapy or standard of care in the third-line setting? There are about 1,400 new patients per year in the U.S. who are diagnosed with the disease.
This #RareDiseaseDay, learn more about #WM and Mustang Bio’s ongoing MB-106 Phase 1/2 trial here: bit.ly/49Ku9KW #CD20-targetedCAR T-cell #WaldenstromMacroglobulinemia $MBIO
#DYK X-Linked Severe Combined Immunodeficiency (XSCID), also commonly known as #BubbleBoyDisease, is a rare mutation in the interleukin 2 receptor gamma (IL2RG) gene that makes a newborn immunocompromised?
There are about 30-40 new patients per year in the U.S. who are diagnosed with the disease and without treatment, most patients do not live past the age of one.
This #RareDiseaseDay, learn more Mustang Bio’s MB-117 and MB-217 gene therapies to treat XSCID here: bit.ly/49Ku9KW #XSCID #BubbleBoyDisease $MBIO
#DYK recurrent glioblastoma (GBM) is a rare and aggressive #braincancer that impacts approximately 12,000 patients in the US annually? Mustang is developing MB-109, a CAR-T cell therapy and oncolytic virus combination, to potentially treat recurrent GBM more effectively.
Get ready for #RareDiseaseDay on February 29. One out of every 10 Americans is living with a rare disease. $MBIO bit.ly/3uGgFkv
Learn more about the rare diseases that Mustang Bio is developing treatments for at MustangBio.com and check out the NORD site to see how you can #ShowYourStripes in support of the 300 million people with rare diseases and disabilities worldwide.
Reminder: Mustang Bio’s Robert Sexton, VP, Program & Alliance Leadership, will speak at the Reuters Events Pharma exclusive webinar this morning at 10a.m. ET. $MBIO $FBIO For more details: bit.ly/3Hv9MVZ
